Aurinia Pharmaceuticals Inc (NASDAQ:AUPH): Look out for Analysts’ Recommendation

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has grabbed the attention from analysts, when it saw a value decrease of -3.68% or -0.27 points in the last trading session. A total of 2.63M shares exchanged hands during the intra-day trade compared with its average trading volume of 5.01M shares, while its relative volume stands at 0.28. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a market cap of $610.38M and the number of outstanding shares have been calculated 78.45M.

When taking a look at recommendations from analysts, investors can use the average brokerage recommendation score to determine the consensus take on a stock. The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc) made by the brokerage firms for a given stock. The ABR rank is displayed in the range of 1 to 5 where 1 represents a Strong Buy and 5 a Strong Sell. The ABR is solely based on brokerage recommendations. It’s important to note that analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) currently have an ABR of 1.22, number of Recs in ABR is 6 while industry rank of the company by ABR is 150 of 265.

Out of the brokerage recommendations 5 rate Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) stock a Strong Buy, 0 rate the stock a Buy, 1 rate Hold, 0 rate Sell and 0 recommend a Strong Sell.

Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $11.58 on the stock, this valuation is based on 6 number of opinions with standard deviation of 1.67. Most recently Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s price target was revised on 05/15/17. The most optimistic analyst sees the stock reaching $14 while the most conventional has $10 target price if we look at the price target with an optimistic approach it has upside potential of 42% from its recent closing price of $7.06.

Historically, if we have a peek at price target revisions, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s price target was revised by the analysts two weeks back on 04/25/17 to set its target price at $11.80 where its twelve month high target price was set at $14 and low at $11 while demonstrating the standard deviation of 1.30.

In order to check on the sell-side rational, we can also take a peek at some technical indicators. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s price sits -4.72% off from its 50-day moving average of $7.10 and 72.19% far from the stock’s 200-day moving average which is $4.64. Shares are trading -33.02% away from the 52-week high mark of $10.54 and +306.21% far from the 52-week bottom of $1.74. The stock hit its 52-week high on 03/13/17, and 52-week low on 08/15/16. The average true range, a measure of volatility is at 0.41, however its weekly and monthly volatility is 7.23%, 5.88% respectively. The company’s Relative Strength Index which shows price strength currently stands at 42.82.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) as of recent trade, has shown weekly downbeat performance of-3.95% which was maintained at 3.82% in 1-month period. The year-to-date (YTD) performance reflected 236.19% positive outlook. During the past three months the stock gain 94.49%, bringing six-month performance to 110.75%.

The stock trailing twelve month P/E ratio is -10.70 along with forward price to earnings ratio of -13.32.

Previous ArticleNext Article